Priveterra Acquisition in an 8-K said its rescheduled shareholder meeting to vote on the proposed merger with Aeon Biopharma was adjouned from yesterday afternoon until June 30 at 4p.m Eastern time. This is the seventh postponement in two weeks.
As with the previous delays, Priveterra cited the need for “additional time for the company to engage with its stockholders.”
Stockholders who wish to withdraw their redemptions may still do so prior to the rescheduled meeting.
Priveterra in April reduced the minimum cash closing condidition to $40 million from the original $45 million. Terms also allow either party to terminate the deal if it does not close by July 31.
AEON is a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions. Read more.
